Scott T Aaronson
Overview
Explore the profile of Scott T Aaronson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aaronson S, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, et al.
Am J Psychiatry
. 2025 Jan;
182(1):104-113.
PMID: 39741440
Objective: Depression varies along a difficulty-to-treat spectrum. Patients whose illness fails to respond to at least five treatments may be considered to have severely treatment-resistant depression (TRD). The objective of...
2.
de Leon V, Allen R, Quevedo J, Riva-Posse P, Aaronson S, Berger M, et al.
J Affect Disord
. 2024 Dec;
374:619-629.
PMID: 39722333
Background: Suicide attempts are a major concern in major depressive disorder (MDD), especially for those with multiple prior unsuccessful treatment trials. This report compares baseline demographic, clinical features, and treatment...
3.
Garzon J, Elmaadawi A, Aaronson S, Schrodt Jr G, Holbert R, Zuckerman S, et al.
J Child Adolesc Psychopharmacol
. 2024 Dec;
35(2):99-108.
PMID: 39718805
Transcranial magnetic stimulation (TMS) is a promising intervention for adolescents with treatment-resistant depression (TRD). However, the durability of TMS-related improvement in adolescents is unclear. This 6-month study followed adolescents with...
4.
Conway C, Aaronson S, Sackeim H, George M, Zajecka J, Bunker M, et al.
Brain Stimul
. 2024 Dec;
PMID: 39706521
Background: Few treatments are available for individuals with marked treatment-resistant depression (TRD). Objective: Evaluate the safety and effectiveness of FDA-approved adjunctive vagus nerve stimulation (VNS) in patients with marked TRD....
5.
Goodwin G, Aaronson S, Alvarez O, Carhart-Harris R, Chai-Rees J, Croal M, et al.
J Affect Disord
. 2024 Dec;
372():523-532.
PMID: 39706482
Objective: To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression. Methods: For treatment-resistant depression, 233 participants received a single dose of 25, 10, or...
6.
Rush A, Conway C, Aaronson S, George M, Riva-Posse P, Dunner D, et al.
Brain Stimul
. 2024 Dec;
PMID: 39701918
Background: Depression treatments aim to minimize symptom burden and optimize quality of life (QoL) and psychosocial function. Objective: Compare the effects of adjunctive versus sham vagus nerve stimulation (VNS) on...
7.
Sackeim H, Aaronson S, Bunker M, Conway C, George M, McAlister-Williams R, et al.
J Psychiatr Res
. 2024 Jun;
176:325-337.
PMID: 38917723
All definitions of treatment-resistant depression (TRD) require that patients have experienced insufficient benefit from one or more adequate antidepressant trials. Thus, identifying "failed, adequate trials" is key to the assessment...
8.
9.
Aaronson S, Goldwaser E, Croarkin P, Geske J, LeMahieu A, Sklar J, et al.
J Clin Psychiatry
. 2024 May;
85(2).
PMID: 38780536
Repetitive transcranial magnetic stimulation (rTMS) is a standard treatment approach for major depressive disorder. There is growing clinical experience to support the use of high-frequency left-sided rTMS in bipolar depression....
10.
Aaronson S, van der Vaart A, Sackeim H
JAMA Psychiatry
. 2024 Apr;
81(6):634.
PMID: 38598225
No abstract available.